ASCO Issues Guidance on Second-Line Treatment of CRPC

April 25, 2017 – Informed by new clinical evidence, ASCO has issued updated guidance on the use of second-line hormonal therapy for chemotherapy-naïve patients with castration-resistant prostate cancer (CRPC). The provisional clinical opinion (PCO) addresses patients who are asymptomatic, with only biochemical evidence of CRPC, as well as those who have documented metastases and minimal symptoms. Many patients with hormone-sensitive prostate … (leggi tutto)